当前位置: X-MOL首页全球导师 国内导师 › 钱程

个人简介

学习经历 1993.09-1995.02 西班牙Navarra大学内科系,博士后 1990.09-1993.07 西班牙Navarra大学内科学专业,医学博士 1985.09-1988.07 白求恩医科大学免疫学专业,医学硕士 1980.09-1985.07 皖南医学院临床专业,医学学士 工作经历 2019.03-至今 重庆大学附属肿瘤医院肿瘤精准医学研究中心 主任 2009.01-2019.02 第三军医大学西南医院生物治疗中心 主任 2008.01-2008.12 北京大学临床肿瘤医院 教授 1995.03-2007.12 西班牙Navarra大学医学研究中心生物治疗研究室 主任 1995.03-2007.12 西班牙Navarra大学应用医学研究中心 副教授、教授 1980.08-1990.07 北京地坛医院 助理研究员 二、专利 授权国际PCT发明专利2项: 1.Cheng Qian, Susana Mouriño López, and Jesus Prieto. System for packaging of high-capacity adenovirus. PCT/ES 2009/070194 2.Cheng Qian, Susana Cheng Qian, Aiwen Dong, Verónica Fernandez Ruiz, Jie Hu, And Jesus Prieto. Anti-angiogenic agents. PCT/ES 2009/070250 授权国家发明专利8项: 1.钱程、蔡荣、张唯.肿瘤双靶向腺病毒AdCN103及其构建方法和应用. CN 101126100A 2.钱程、蔡荣、夏清梅、骆箐箐.构建内源启动子调控外源基因的新型增殖腺病毒载体。CN 101235387A 3.钱程、刘立、姜威、崔强、蔡荣。晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用。CN 101381742A 4.钱程,刘丽梅,刘春刚,沈俊杰,单娟娟.干扰SIRT1表达试剂在制备抑制肝癌干细胞自我更新的药物中的应用.专利号: ZL 2014 1 0032594.4 5.钱程,刘丽梅,刘春刚,沈俊杰,单娟娟.干扰SIRT1表达试剂在制备抑制肝癌干细胞干性转录因子表达的试剂中的应用.专利号: ZL 2014 1 0032609.7 6.钱程,刘丽梅,刘春刚,沈俊杰,单娟娟.SIRT1抑制剂联合索拉菲尼在制备治疗肝癌的药物中的应用;专利号: ZL 2014 1 0032646.8. 7.钱程,洪娟,赵文旭,沈俊杰,单娟娟.抗肝癌干细胞单克隆抗体及其应用;专利号: ZL 2014 1 0167963.0. 8.钱程,沈俊杰,单娟娟. Matrigel诱导肿瘤细胞逆转为肿瘤干细胞的应用及方法;专利号: ZL 2014 1 0849661.1. 三、主持承担的各级各类科研项目情况 1.国家自然科学基金重大研究计划:“肿瘤去分化与肿瘤微环境相互作用的机制和可视化研究”(91959206),2020-01至2023-12,295万元,主持,在研; 2.国家自然科学基金重点国际合作项目:“F2D在肿瘤微环境调控肝癌侵袭转移中的作用及分子机制研究”(520108025),2016-01至2020-12,282万,主持,在研; 3.国家科技部重点研发计划:“恶性肿瘤免疫治疗关键技术研究”(2016YFC1303400),总经费2528.74万元,执行年限:2016.09-2020.12.首席科学家,主持,在研; 4.重庆市社会事业与民生保障科技创新专项:“疾病精准生物治疗技术研发及应用”,(cstc2016shms-ztzx10006),2016-10至2019-10,290万,主持,结题; 5.重庆大学医工融合项目:“肿瘤微环境在CAR-T治疗实体瘤反应中的作用及机制”,(2019CDYGZD008),2019-06至2022-05,50万,第二负责人,在研; 6.国家科技部“973”项目:“iCSCs和脉管生成为靶标的肿瘤治疗新方法研究”(2004CB518804),经费170万,执行年限2004-2009.主持,结题 7.国家科技部“973”项目:“靶向性、选择性基因表达调控元件及载体的研究”(2004CB518804),经费170万,执行年限2004-2009.主持,结题 8.国家科技部“863”项目:“新型溶瘤腺病毒载体靶向介导siRNA簇的研究”(2006AA02Z126),经费90万元,执行年限2006.01-2009.12. 主持,结题 9.国家自然科学基金重大国际合作项目:“CIK细胞介导溶瘤腺病毒靶向治疗肝癌的实验研究”(81020108026),经费200万元,执行年限2011.01-2013.12.主持,结题 10.国家自然科学基金重点项目:“SIRT1在调控肝癌干细胞自我更新中的作用及分子机制”(81330048), 经费290万,执行年限:2014.01-2018.12.主持,结题 11.国家自然科学基金重大项目:“结直肠癌EMT模型的建立与转移干预的研究”(8190423), 经费250万元,执行年限2011.1-2014.12.主持,结题 12.重庆市科技研发基地建设计划(国际科技合作)项目:“中国-西班牙肿瘤生物治疗国际联合研发中心”(cstc2013gjhz10001),经费150万元,执行年限:2014.3-2015.12.主持,结题.

研究领域

研究方向:肿瘤发生的致病机制及生物治疗

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

文章: 1. Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C,Qian C(通讯作者).Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.Gastroenterology. 2020 Feb;158(3):664-678(IF:19.233). 2. Heng G, Jia J, Li S, Fu G, Wang M, Qin D, Li Y, Pei L, Tian X, Zhang J, Wu Y, Xiang S, Wan J, Zhu W, Zhang P, Zhang Q, Peng X, Wang L, Wang P, Wei Z, Zhang Y, Wang G, Chen X, Zhang C, Sun Y, Zhao W, Fan Y, Yang Z, Chen J,Qian C(通讯作者).Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.Clin Cancer Res. 2020 Apr 1;26(7):1606-1615.(IF:8.911). 3. Wei Z, Jia J, Heng G, Xu H, Shan J, Wang G, Liu C, Xia J, Zhou H, Wu M, Yang Z, Wang M, Xiong Z, Huang H, Liu L,Qian C(通讯作者).Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem cells.Hepatology,2019 Oct;70(4):1197-1213. (IF:14.971). 4. Shan J,ShenJ,WuM,ZhouH,FengJ,YaoC,YangZ,MaQ,LuoY,Wang Y,Qian C(通讯作者).Tcf7l1 acts as a suppressor for the self-renewal of liver cancer stem cells and is regulated by IGF/MEK/ERK signaling independent of β-catenin.STEM CELLS 2019;37:1389–1400(IF:5.614) 5. Chen X,HuanH,LiuC,LuoY,ShenJ,ZhouY,ZhangZ,Qian C(通讯作者).Deacetylation of β-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells.Cancer Letters 463 (2019) 1–10(IF:6.508). 6. Xu Y, Xu H, Li M, Wu H, Guo Y, Chen J, Shan J, Chen X, Shen J, Ma Q, Liu J, Wang M, Zhao W, Hong J, Qi Y, Yao C, Zhang Q, Yang Z,Qian C(通讯作者),Li J.KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.Cancer Lett.2019 Jul 10;454:78-89.(IF:6.508) 7. Chen L, Li S, Wang M, Li Y, Xiong Z, Zhang R, Xu Y, Huang Z, Wang L, Wang S, Yang Z,Qian C(通讯作者). Expansion deficiency of CAR-T cells in patients with lymphoma and resolution by T cell purification.Br J Haematol. 2019 Jul;186(2):340-343.(IF:5.206) 8. Zhang C, Kong PY, Li S, Chen T, Ni X, Li Y, Wang M, Liu Y, Gao L, Gao L, Peng XG, Sun AH, Wang P, Yang Z, Zhang X,Qian C(通讯作者).Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.J Immunother. 2018 Jul/Aug;41(6):306-311.(IF:3.455) 9. Li S, Zhang J, Wang M, Fu G, Li Y, Pei L, Xiong Z, Qin D, Zhang R, Tian X, Wei Z, Chen R, Chen X, Wan J, Chen J, Wei X, Xu Y, Zhang P, Wang P, Peng X, Yang S, Shen J, Yang Z, Chen J,Qian C(通讯作者).Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.Br J Haematol. 2018 May;181(3):360-371.(IF:5.206) 10. Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C, Shan J, Shen J,Qian C(通讯作者).LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells.Cancer Res.2018 Feb 15;78(4):938-949.(IF:8.378) 11. Zhang Q, Yang Z, Shan J, Liu L, Liu C, Shen J, Chen X, Xu Y, Chen J, Ma Q, Yang L,Qian C(通讯作者).MicroRNA-449a maintains self-renewal in liver cancer stem-like cells by targeting Tcf3.Oncotarget. 2017 Nov 27;8(66):110187-110200.(IF:5.168) 12. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, Luo Y, Zhang Q, Liu L, Qin H, Liu W, Wu F, Chen W, Pan F, Zhang X, Bie P, Liang H, Pecher G,Qian C(通讯作者).Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+Metastatic Colorectal Cancers.Mol Ther. 2017 May 3;25(5):1248-1258(IF:6.688) 13. Xiang J, Sun H,Su L, Liu L, Shan J, Shen J, Yang Z, Chen J, Zhong X, Ávila MA, Yan X, Liu C,Qian C(通讯作者).Myocyte enhancer factor 2D promotes colorectal cancer angiogenesis downstream of hypoxia-inducible factor 1α.Cancer Lett.2017 Aug 1;400:117-126.(IF:6.375) 14. Zhang H,Liu L,Liu C,Pan J,Lu G,Zhou Z,Chen Z,Qian C(通讯作者).Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.Oncotarget.2017 Mar 13. doi: 10.18632/oncotarget.16156.(IF:5.168) 15. Liu C,Liu L,ChenX,Cheng J,Zhang H,Shen J,Shan J, Xu Y,Yang Z,Lai M,Qian C(通讯作者).Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma.Hepatology,2016;64(1):117-29.(IF:14.978) 16. Liu L,Liu C,Zhang Q,Shen J,Zhang H,Shan J,Duan G,GuoD,Chen X,Cheng,J,Xu Y,Yang Z,Yao C, Lai M,Qian C(通讯作者).SIRT1-Mediated Transcriptional Regulation of SOX2 is important for Self-Renewal of Liver Cancer Stem Cells.Hepatology, 2016; 64(3): 814 - 827.(IF:14.978) 17. Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C,Qian C(通讯作者).MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett.2016 Feb 28;371(2):171-81(IF: 6.375) 18. Cheng F, Su L, Yao C, Liu L, Shen J, Liu C, Chen X, Luo Y, Jiang L, Shan J, Chen J, Zhu W, Shao J,Qian C(通讯作者).SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression.Cancer Lett. 2016 Jun 1;375(2):274-83.(IF:6.375) 19. Luo Y, Yang Z, Su L, Shan J, Xu H, Xu Y, Liu L, Zhu W, Chen X, Liu C, Chen J, Yao C, Cheng F, Zhang C, Ma Q, Shen J,Qian C(通讯作者).Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-κB and JAK/STAT3 signaling in human hepatocellular carcinoma.Cancer Lett. 2016 Jun 1;375(2):390-9.(IF:6.375) 20. Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F, Shan J, Chen J, Li F, Liu L, Liu C, Xu Y, Jiang L, Guo D, Prieto J, Ávila MA, Shen J,Qian C(通讯作者).MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.Cancer Res. 2016 Sep 1;76(17):5054-67.(IF:9.122)

推荐链接
down
wechat
bug